SYNCOMF19.23

Syncom Formulations (India) Limited

· Pharma & Health
₹ CrorePeersHESTERBIONGLFINEWINDLASJAGSNPHARMAMRUTANJANINDOCOSAIPARENTMcap ₹1,808 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth+76.6+5.2
EBITDA Growth+82.6+43.0
EBIT Growth+96.3+44.9
Net Income Growth+95.3+54.6
EPS Growth+67.6+42.1
Total Assets Growth+2.1+29.2
Total Equity Growth+18.7+21.3
Cash from Operations Growth+493.3+147.8
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.